Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Phase 2
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000002972
- Lead Sponsor
- Kyorin University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1)Massive pleural or abdominal effusion 2)Uncontrolled hypertension 3)Uncontrolled heart disease 4)Evidence of Myocardial infarction witin 6 months 5)Active infection (except viral hepatitis) 6)Active gastrointestinal bleeding or ulcer 7)active double cancer 8)encephalopacy or severe mental disorder 9)severe drug allergy 10)pregnancy or lactaing females 11)inadequate for administration orally 12)Inadequate physical condition,as diagnosed by primary physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Adverse events Response rate Overall survival